文献速递冠心病外科肺外科先天性心脏病外科

猪心与猪肺异种移植:现状

Pig heart and lung xenotransplantation: Present status.
PubMed 文献 · J Heart Lung Transplant · 2022-05-13

综述总结猪心脏和肺异种移植的现状。通过删除三种猪碳水化合物异种抗原表达及转入人保护蛋白等基因修饰,联合阻断CD40/CD154共刺激通路免疫抑制,狒狒接受生命支持性猪心移植物存活近9个月。猪心可能有效桥接同种移植,作为终点治疗的价值尚不确定;猪肺异种移植因额外免疫生物学问题存活仍以天或周计。

要点

  • 基因修饰猪心联合CD40/CD154共刺激阻断使狒狒存活近9个月。
  • 猪心可能有效桥接同种移植,但作为终点治疗的价值尚不确定。
  • 猪肺异种移植因额外复杂免疫生物学问题存活仍以天或周计。

核心结论

  • 猪心异种移植可能有效桥接同种移植,但其作为终点治疗的价值尚不确定。
  • 猪肺异种移植因额外复杂免疫生物学问题,临床前存活仍以天或周计。

研究设计与样本

  • 综述,总结猪心与猪肺异种移植的现状,涵盖基因修饰策略、免疫抑制方案及临床前与临床结果。

主要发现

  • 删除三种已知猪碳水化合物异种抗原表达和转基因引入人保护蛋白(如补体调节蛋白)两条途径,已基本克服猪作为器官来源的障碍。
  • 这些基因修饰联合基于阻断CD40/CD154共刺激通路的免疫抑制治疗,使狒狒接受生命支持性猪心移植物存活近9个月。
  • 马里兰大学医学中心的初期临床成功强化了鼓舞人心的临床前结果。
  • 猪肺异种移植因额外复杂免疫生物学问题,临床前存活仍以天或周计。

关键数值与推荐

  • 猪心异种移植首次正式临床试验可能纳入无法获得同种移植的患者、有机械循环支持禁忌证的患者、需要再次移植的患者或群体反应性抗体水平高的患者。
  • 复杂先天性心脏病婴儿也应被考虑。

临床怎么用

  • 作者认为猪心异种移植可能有效桥接同种移植,但作为终点治疗的价值尚不确定。
  • 作者提出猪心异种移植首次正式临床试验可能纳入无法获得同种移植、有机械循环支持禁忌证、需要再次移植或群体反应性抗体水平高的患者,复杂先天性心脏病婴儿也应被考虑。

局限性

  • 猪心异种移植作为终点治疗的价值尚不确定。
  • 猪肺异种移植因额外复杂免疫生物学问题,临床前存活仍以天或周计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent pig heart transplant in a patient at the University of Maryland Medical Center has stimulated renewed interest in the xenotransplantation of organs from genetically engineered pigs. The barriers to the use of pigs as sources of organs have largely been overcome by 2 approaches - (1) the deletion of expression of the three known pig carbohydrate xenoantigens against which humans have preformed antibodies, and (2) the transgenic introduction of human 'protective' proteins, such as complement-regulatory proteins. These gene modifications, coupled with immunosuppressive therapy based on blockade of the CD40/CD154 costimulation pathway, have resulted in survival of baboons with life-supporting pig heart grafts for almost 9 months. The initial clinical success at the University of Maryland reinforces encouraging preclinical results. It suggests that pig hearts are likely to provide an effective bridge to an allotransplant, but their utility for destination therapy remains uncertain. Because of additional complex immunobiological problems, the same approach has been less successful in preclinical lung xenograft transplantation, where survival is still measured in days or weeks. The first formal clinical trials of pig heart transplantation may include patients who do not have access to an allotransplant, those with contraindications for mechanical circulatory support, those in need of retransplantation or with a high level of panel-reactive antibodies. Infants with complex congenital heart disease, should also be considered.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Chaban R, Cooper DKC, Pierson RN, et al. Pig heart and lung xenotransplantation: Present status. J Heart Lung Transplant. 2022. PMID: 35659792. doi:10.1016/j.healun.2022.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。